PURPOSE: To introduce a novel approach for the time-dependent quantification of risk factors for prostate cancer (PCa) detection after an initial negative biopsy. PATIENTS AND METHODS: Data for 1,871 men with initial negative biopsies and at least one follow-up biopsy were available. Piecewise exponential regression models were developed to quantify hazard ratios (HRs) and define cumulative incidence curves for PCa detection for subgroups with specific patterns of risk factors over time. Factors evaluated included age, race, serum prostate-specific antigen (PSA) concentration, PSA slope, digital rectal examination, dysplastic glands or prostatitis on biopsy, ultrasound gland volume, urinary symptoms, and number of negative biopsies. RESULTS: Four hundred sixty-five men had PCa detected, after a mean follow-up time of 2.8 years. All of the factors were independent predictors of PCa detection except for PSA slope, as a result of its correlation with time-dependent PSA level, and race. PSA (HR = 3.90 for > 10 v 2.5 to 3.9 ng/mL), high-grade prostatic intraepithelial neoplasia/atypical glands (HR = 2.97), gland volume (HR = 0.39 for > 50 v < 25 mL), and number of repeat biopsies (HR = 0.36 for two v zero repeat biopsies) were the strongest predictors. Men with high-risk versus low-risk event histories had a 20-fold difference in PCa detection over 5 years. CONCLUSION: Piecewise exponential models provide an approach to longitudinal analysis of PCa risk that allows clinicians to see the interplay of risk factors as they unfold over time for individual patients. With these models, it is possible to identify distinct subpopulations with dramatically different needs for monitoring and repeat biopsy.
PURPOSE: To introduce a novel approach for the time-dependent quantification of risk factors for prostate cancer (PCa) detection after an initial negative biopsy. PATIENTS AND METHODS: Data for 1,871 men with initial negative biopsies and at least one follow-up biopsy were available. Piecewise exponential regression models were developed to quantify hazard ratios (HRs) and define cumulative incidence curves for PCa detection for subgroups with specific patterns of risk factors over time. Factors evaluated included age, race, serum prostate-specific antigen (PSA) concentration, PSA slope, digital rectal examination, dysplastic glands or prostatitis on biopsy, ultrasound gland volume, urinary symptoms, and number of negative biopsies. RESULTS: Four hundred sixty-five men had PCa detected, after a mean follow-up time of 2.8 years. All of the factors were independent predictors of PCa detection except for PSA slope, as a result of its correlation with time-dependent PSA level, and race. PSA (HR = 3.90 for > 10 v 2.5 to 3.9 ng/mL), high-grade prostatic intraepithelial neoplasia/atypical glands (HR = 2.97), gland volume (HR = 0.39 for > 50 v < 25 mL), and number of repeat biopsies (HR = 0.36 for two v zero repeat biopsies) were the strongest predictors. Men with high-risk versus low-risk event histories had a 20-fold difference in PCa detection over 5 years. CONCLUSION: Piecewise exponential models provide an approach to longitudinal analysis of PCa risk that allows clinicians to see the interplay of risk factors as they unfold over time for individual patients. With these models, it is possible to identify distinct subpopulations with dramatically different needs for monitoring and repeat biopsy.
Authors: Ernesto Lopez-Corona; Makoto Ohori; Peter T Scardino; Victor E Reuter; Mithat Gonen; Michael W Kattan Journal: J Urol Date: 2003-10 Impact factor: 7.450
Authors: Andrew J Vickers; Tineke Wolters; Caroline J Savage; Angel M Cronin; M Frank O'Brien; Monique J Roobol; Gunnar Aus; Peter T Scardino; Jonas Hugosson; Fritz H Schröder; Hans Lilja Journal: J Urol Date: 2010-09 Impact factor: 7.450
Authors: Stacy Loeb; Edward F Vonesh; E Jeffrey Metter; H Ballentine Carter; Peter H Gann; William J Catalona Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Axel Krieger; Iulian I Iordachita; Peter Guion; Anurag K Singh; Aradhana Kaushal; Cynthia Ménard; Peter A Pinto; Kevin Camphausen; Gabor Fichtinger; Louis L Whitcomb Journal: IEEE Trans Biomed Eng Date: 2011-11 Impact factor: 4.538
Authors: Joan Alexander; Jude Kendall; Jean McIndoo; Linda Rodgers; Robert Aboukhalil; Dan Levy; Asya Stepansky; Guoli Sun; Lubomir Chobardjiev; Michael Riggs; Hilary Cox; Inessa Hakker; Dawid G Nowak; Juliana Laze; Elton Llukani; Abhishek Srivastava; Siobhan Gruschow; Shalini S Yadav; Brian Robinson; Gurinder Atwal; Lloyd C Trotman; Herbert Lepor; James Hicks; Michael Wigler; Alexander Krasnitz Journal: Cancer Res Date: 2017-11-27 Impact factor: 12.701
Authors: Mark W Ball; Ashley E Ross; Kamyar Ghabili; Chunwoo Kim; Changhan Jun; Doru Petrisor; Li Pan; Jonathan I Epstein; Katarzyna J Macura; Dan S Stoianovici; Mohamad E Allaf Journal: Urology Date: 2017-07-19 Impact factor: 2.649
Authors: William A Sterling; Joseph Weiner; David Schreiber; Komal Mehta; Jeffrey P Weiss Journal: Int Urol Nephrol Date: 2016-08-31 Impact factor: 2.370
Authors: Axel Krieger; Sang-Eun Song; Nathan B Cho; Iulian Iordachita; Peter Guion; Gabor Fichtinger; Louis L Whitcomb Journal: IEEE ASME Trans Mechatron Date: 2011-10-17 Impact factor: 5.303
Authors: Matthew Truong; Bing Yang; Andrew Livermore; Jennifer Wagner; Puspha Weeratunga; Wei Huang; Rajiv Dhir; Joel Nelson; Daniel W Lin; David F Jarrard Journal: J Urol Date: 2012-11-15 Impact factor: 7.450